CLAIM CARD
Within this corpus, some tensions arise from differences in study design, endpoint selection, and effect direction attribution. Samuel 2020 reports no primary efficacy data of its own but frames the COLCOT findings within a cost-effectiveness analysis. Pan 2023's positive peri-operative findings contrast with the null safety signals reported by Broekhoven 2022, reflecting the different biological contexts — acute surgical inflammation versus chronic stable disease — under which colchicine was administered.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022